Delta Asset Management LLC TN Has $2.60 Million Position in Pfizer Inc. (NYSE:PFE)

Delta Asset Management LLC TN raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 15.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 97,994 shares of the biopharmaceutical company's stock after purchasing an additional 13,361 shares during the period. Delta Asset Management LLC TN's holdings in Pfizer were worth $2,600,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of PFE. AssuredPartners Investment Advisors LLC bought a new stake in Pfizer in the fourth quarter valued at about $1,081,000. NEOS Investment Management LLC increased its holdings in shares of Pfizer by 31.8% in the 4th quarter. NEOS Investment Management LLC now owns 350,036 shares of the biopharmaceutical company's stock valued at $9,286,000 after acquiring an additional 84,536 shares during the last quarter. Amica Mutual Insurance Co. raised its position in shares of Pfizer by 44.7% during the 4th quarter. Amica Mutual Insurance Co. now owns 157,064 shares of the biopharmaceutical company's stock valued at $4,167,000 after acquiring an additional 48,541 shares in the last quarter. UniSuper Management Pty Ltd lifted its stake in Pfizer by 34.8% during the fourth quarter. UniSuper Management Pty Ltd now owns 349,745 shares of the biopharmaceutical company's stock worth $9,279,000 after purchasing an additional 90,289 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Pfizer by 8.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 9,013,007 shares of the biopharmaceutical company's stock worth $239,656,000 after purchasing an additional 674,556 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Performance

NYSE PFE traded up $0.19 during midday trading on Friday, hitting $25.20. The company had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. The firm has a fifty day simple moving average of $26.06 and a two-hundred day simple moving average of $26.92. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $142.93 billion, a price-to-earnings ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.